Douglas Guenter
Family Medicine · Oswego, NYNPI 1659450989
Payments from drug & device makers
Across 395 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$994
- GSK$658
- Pfizer$649
- AstraZeneca$499
- Abbott$435
- Novo Nordisk$425
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,607100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $994 |
| GSK | 44 | $658 |
| Pfizer | 57 | $649 |
| AstraZeneca | 28 | $499 |
| Abbott | 39 | $435 |
| Novo Nordisk | 28 | $425 |
| Boehringer Ingelheim | 16 | $344 |
| Amgen | 17 | $297 |
| Exact Sciences | 11 | $280 |
| Lilly USA, LLC | 13 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $162 |
| Corcept Therapeutics | 5 | $151 |
| Otsuka America Pharmaceutical, Inc. | 6 | $150 |
| Phathom Pharmaceuticals, Inc. | 6 | $147 |
| Alk-abello, Inc | 6 | $141 |
| Lundbeck LLC | 5 | $137 |
| Mylan Specialty L.p. | 4 | $96 |
| Astellas Pharma US Inc | 5 | $93 |
| Sumitomo Pharma America, Inc. | 4 | $86 |
| Novartis | 5 | $83 |
| Bayer | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Amarin Pharma, Inc. | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Eisai Inc. | 2 | $31 |
| Corium, LLC | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Merck | 1 | $27 |
| Insulet Corporation | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,619 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 41 | $63,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $59,747 |
| JardianceEmpagliflozin | 43 | $51,880 |
| EliquisApixaban | 32 | $32,410 |
| XareltoRivaroxaban | 18 | $21,917 |
| JanuviaSitagliptin Phosphate | 13 | $16,796 |
| OzempicSemaglutide | 13 | $14,184 |
| TradjentaLinagliptin | 15 | $11,185 |
| MyrbetriqMirabegron | 11 | $10,621 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,981 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,759 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 21 | $6,622 |
| Levothyroxine Sodium | 263 | $5,611 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,176 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 17 | $3,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta, Shingrix | $658 | $74,327113 claims |
| AstraZenecaFarxiga, Symbicort | $499 | $70,98066 claims |
| Boehringer IngelheimJardiance, Tradjenta | $344 | $63,06558 claims |
| PfizerEliquis | $649 | $32,41032 claims |
| Johnson & JohnsonXarelto | $29 | $21,91718 claims |
| MerckJanuvia | $27 | $16,79613 claims |
| Novo NordiskOzempic | $425 | $14,18413 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $10,62111 claims |
| AbbVieSynthroid | $994 | $1,61219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Oswego
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.